Mapping the Genomic Response to Chemotherapy Agents

The National Center for Biotechnology Information (NCBI) is pivotal in genomic research. A recent study tackled drug resistance in cancer, a major barrier to effective treatment. Researchers used machine learning to predict resistance to gemcitabine and carboplatin in cancer cell lines, employing classifiers like Gradient Boosting, Logistic Regression, Random Forest, and Naive Bayes. By analyzing genomic interaction features such as read pair counts and p-values, the models were rigorously trained and validated.Results showed, the Random Forest classifier achieved the highest performance, demonstrating an impressive test accuracy of 89.80%. It also exhibited robust precision of 0.91, recall (sensitivity) of 0.89, and an F1-score of 0.90. Additionally, the classifier had a specificity of 90.38%, highlighting its effectiveness in both identifying positive instances and accurately classifying negative ones. This study demonstrates the potential of machine learning in personalized medicine, opening the door to novel therapeutic targets and individualized therapies.